Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Sundar Jagannath, MD
Published: Monday, Mar 27, 2017



Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Immunotherapy approaches may overcome mutational burdens or drug resistance in the cancer cells of this disease, says Jagannath. Monoclonal antibodies such as daratumumab (Daralex) and elotuzumab (Empliciti) are being used in newly diagnosed patients with myeloma. Additionally, checkpoint inhibitors may move upfront if they show positive results in the relapsed setting.

According to Jagannath, immuno-oncology may have a huge impact on the treatment landscape of multiple myeloma.



Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Immunotherapy approaches may overcome mutational burdens or drug resistance in the cancer cells of this disease, says Jagannath. Monoclonal antibodies such as daratumumab (Daralex) and elotuzumab (Empliciti) are being used in newly diagnosed patients with myeloma. Additionally, checkpoint inhibitors may move upfront if they show positive results in the relapsed setting.

According to Jagannath, immuno-oncology may have a huge impact on the treatment landscape of multiple myeloma.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x